The Western States (WS) Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) promotes evidence-based drug abuse prevention and treatment services through continued participation in the CTN. The Node 1) designs and implements clinical trials of evidence-based treatments of addiction through rapid recruitment of diverse study participants in partnership with NIDA and the CTN, 2) generates peer-reviewed publications in collaboration with treatment providers and other nodes, and 3) uses the CTN as a platform for training, dissemination, and research applications. The Regional Research and Training Center includes talented faculty and staff from Oregon Health & Science Center and University of California, San Francisco as well as leaders of affiliated healthcare partners providing integrated primary care and substance use disorder treatment. The Node was created in 2010 as an amalgam of two CTN Nodes--California-Arizona and Oregon/Hawaii (a charter member of the CTN). The Node was highly successful, during the current award, participating in 10 CTN trials, co-leading two of these and leading one; reporting results of CTN main studies, ancillary, and research using the CTN platform in 100+ publications, and actively disseminating evidence- based practices in 200 presentations. Node investigators also sought and received awards for 10 studies that used the CTN as a platform for research. Eight WS Node healthcare programs recruited over 1,300 participants into CTN studies. In the coming grant period the Node expands to include three national and regional primary care and HIV primary care research networks: OCHIN, the HIV Research Network, and the Oregon Rural Practice-Based Research Network (ORPRN). The Node retains core addiction treatment centers experienced in CTN protocols and exploits their links with primary care: Adapt (Roseburg, OR), CODA (Portland, OR) HealthRIGHT 360 (San Francisco, CA), La Frontera (Tucson, AZ), NARA (Portland, OR), and Signal Behavioral Health Network (Denver, CO). The Node's research agenda proposes study concepts that evaluate three strategies to integrate and enhance addiction treatment within healthcare settings. Study 1 builds a patient registry for HCV infection and tests a multi-contact brief intervention for alcohol use. Study 2 extends the registry testing a candidate therapeutic HIV vaccine. Study 3, a test of reverse integration (primary care clinicians in addiction treatment settings), assesses naloxone distribution and education to reduce fatal and nonfatal opioid overdoses and measures impact on return to use. Finally the WS Node continues to use the CTN as a platform for training, dissemination, and research applications. The Node has the potential to accelerate the advancement of integrated primary care and addiction in the coming years.

Public Health Relevance

This renewal application to conduct research in the NIDA Clinical Trials Network has broad public health implications focused on developing and testing ways to better treat medical problems and addiction through integrated care. The project will conduct clinical trials of treatments for drug use disorders in the context of primary care addressing hepatitis C, HIV, and opioid overdose--topics of urgent national importance. This research can accelerate the advancement of providing integrated treatments for medical problems and addiction in the coming years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
3UG1DA015815-14S1
Application #
9117842
Study Section
Special Emphasis Panel (ZDA1-JXR-D (11))
Program Officer
Dobbins, Ronald
Project Start
2002-09-30
Project End
2020-05-31
Budget Start
2015-09-01
Budget End
2016-05-31
Support Year
14
Fiscal Year
2015
Total Cost
$870,391
Indirect Cost
$174,538
Name
University of California San Francisco
Department
Psychiatry
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Havens, Jennifer R; Walsh, Sharon L; Korthuis, P Todd et al. (2018) Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. Curr HIV/AIDS Rep 15:315-323
Kohno, Milky; Dennis, Laura E; McCready, Holly et al. (2018) A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend 192:186-192
Korthuis, P Todd; Edelman, E Jennifer (2018) Substance use and the HIV care continuum: important advances. Addict Sci Clin Pract 13:13
Holton, Dwight; White, Elizabeth; McCarty, Dennis (2018) Public Health Policy Strategies to Address the Opioid Epidemic. Clin Pharmacol Ther 103:959-962
Anastas, Tracy; Waddell, Elizabeth Needham; Howk, Sonya et al. (2018) Building Behavioral Health Homes: Clinician and Staff Perspectives on Creating Integrated Care Teams. J Behav Health Serv Res :
McCarty, Dennis; Gu, Yifan; Renfro, Stephanie et al. (2018) Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion. J Subst Abuse Treat 94:24-28
Sorensen, James L; Llamas, Jasmin D (2018) Process Evaluation of a Community Outpatient Program Treating Substance Use Disorders. J Community Psychol 46:844-855
Springer, Sandra A; Korthuis, P Todd; Del Rio, Carlos (2018) Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Ann Intern Med 169:335-336
Campbell, Aimee N C; Barbosa-Leiker, Celestina; Hatch-Maillette, Mary et al. (2018) Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict 27:465-470

Showing the most recent 10 out of 90 publications